Hints and tips:
Related Topics
...Investors will still have to wait until at least 2026 for an approved oncology product....
...To make up for the shortfall in its pipeline, the US drugmaker earlier this year announced plans to buy Seagen, an oncology drugmaker, for $43bn; a deal Pfizer said it expected to close on Thursday....
...He added that oncology continued to be “the largest growth driver in global medicine” so the deal contributed to Pfizer’s near and long-term financial goals....
...Shares in oncology-focused biotech Seagen, which Pfizer has agreed to buy for $43bn, also fell amid fears the agency could target other deals in the sector....
...It rejected Illumina’s claim that the acquisition would accelerate the rollout of Grail’s oncology tests and save lives, noting the company’s projections were “vague, self-serving, and unsupported”....
...The company, whose four approved oncology treatments generated $2bn in sales last year, should help the pharmaceutical company offset some of an expected decline in revenue as the Covid vaccine boom fades...
...The oncology-focused biotech agreed a $43bn deal to be acquired by Pfizer....
...The US drugmaker was reportedly in talks with oncology-focused Seagen about a potential deal last year but did not move forward with a transaction....
...revenue, has spent more than ¥1tn ($7.3bn) in overseas acquisitions and partnerships since 2007, including its $3bn purchase of US drugmaker Audentes Therapeutics in 2020 and its $3.8bn takeover of US-based oncology...
...Denton said the company was adjusting its business development strategy after its $43bn acquisition in March of oncology-focused biotech Seagen to focus more on shareholder returns....
...He said Pfizer had made great progress in oncology over the past decade, building what was a pipeline of only two or three molecules into one of the largest therapeutic areas in the group....
...directors have warned that Illumina’s battles with antitrust regulators and activist investor Carl Icahn over its ownership of the cancer screening company threaten to hamper access to potentially life-saving oncology...
...Both companies have a strong presence in the oncology market, so a tie-up would inevitably attract antitrust scrutiny. To be sure, the technologies used are different....
...The global oncology market is one of the fastest-growing within the pharmaceutical sector and was worth $286bn in 2021, according to Precedence Research, a market research firm....
...It has also narrowed its focus on two therapeutic areas: oncology and neurology....
...SeaGen — formerly known as Seattle Genetics — has four approved oncology treatments....
..., AstraZeneca’s chief executive, said on Friday that Enhertu’s recent results were “a truly outstanding achievement”, describing how they received a standing ovation at the American Society of Clinical Oncology...
...There are other antivirals in development: Miami-based oncology company Veru recently published positive results for its drug, which is both antiviral and anti-inflammatory, showing it reduced deaths in...
...Revenue last year from oncology was up more than 20 per cent from the year before to $10.9bn....
...Smart reads Dwindling dynasties The generation that built Japan Inc is running out of heirs, as the country’s rapidly shrinking population creates a national succession crisis and ample opportunity for...
...Peter Lebowitz, head of J&J’s global oncology division, told the Financial Times that “before 2015, in the early days”, Chinese biotech companies were focused on formulating “slightly better versions of...
...“And don’t we really need to on oncology, dementia and rare diseases?” he adds. “Lawyers are, by their nature, worriers,” he notes....
...AstraZeneca’s innovation in oncology has helped turn round performance at the Anglo-Swedish drugmaker in recent years....
...Among its top priorities will be oncology research. The company is working on 15 candidates for cancer therapies and has also vowed to devote resources to developing malaria and tuberculosis vaccines....
...Sales at its oncology, internal medicine and hospital divisions all posted double-digit sales growth in the first quarter. At 13 times forward earnings, the stock is trading at a fair valuation....
International Edition